Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers

International Journal of Cancer

Volumn 123, Issue 10, 2008, Pages 2254-2259

  Lubet, Ronald A ^a   Fischer, Susan M ^b   Steele, Vernon E ^a   Juliana, M Margaret ^c   Desmond, Renee' ^d   Grubbs, Clinton J ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Kentucky   (United States)

Author keywords

Cancer; PPAR gamma agonist; Rosiglitazone; Urinary bladder

Indexed keywords

CARCINOGEN; HYDROXYBUTYL(BUTYL)NITROSAMINE; NITROSAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER EPITHELIUM; BODY WEIGHT; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; TISSUE MICROARRAY; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; COCARCINOGENESIS; DRUG POTENTIATION; FISCHER 344 RAT;

ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; COCARCINOGENESIS; FEMALE; IMMUNOHISTOCHEMISTRY; PPAR GAMMA; RATS; RATS, INBRED F344; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 53449086678     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23765     Document Type: Article

References (23)

1. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodman DG, Brown CC, Sporn MB. 13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Science 1977;198:743-4.
2. Becci PJ, Thompson HJ, Strum JM, Brown CC, Sporn MB, Moon RC. N-Butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids. Cancer Res 1981;41:927-32.
3. Han SY, Ilopoulos D, Druck T, Guler G, Grubbs CJ, Pereira M, Zhang Z, You M, Lubet RA, Fong LY, Huebner K. CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors. Oncogene 2004;23:3390-8.
4. Lubet RA, Huebner K, Fong LY, Altieri D, Steele VE, Kopelovich L, Kavanaugh C, Juliana MM, Soong SJ, Grubbs CJ. 4-Hydroxybutyl (butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis 2005;26:571-8.
5. Yao R, Yijun Y, Grubbs CJ, Lubet RA, You M. Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 2007;9:207-21.
6. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-602.
7. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, Kitayama W, Wakabayashi K, Konishi Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 specific, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 1998;58:3028-31.
8. Rao KV, Detrisac DJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435-8.
9. Lubet RA, Yang CS, Lee M-J, Hara Y, Kapetanovic IM, Crowell JA, Steele VE, Juliana MM, Grubbs CJ. Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols. Mol Cancer Ther 2007;6:2022-8.
10. Lubet RA, Steele VE, Juliana MM, Yao R, You M, Grubbs CJ. Chemopreventive effects of the EGFr inhibitor Iressa on chemically (OHBBN) induced urinary bladder cancers: histopathologic and biochemical endpoints. AACR-NCI-EORTC Conference on Molecular Targets and Therapeutics 2007; Abstract: 307.
11. Tan NS, Michalik L, Desvergne B, Wahli W. Multiple expression control mechanisms of peroxisome proliferators-activated receptors and their target genes. J Steroid Biochem Mol Bio 2005;93:99-105.
12. Gottardis MM, Bischoff E, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD 1069 (Targretin), an RXR-selective ligand. Cancer Res 1996;56:5566-70.
13. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Brisonette R, Brown PH. The retinoid X receptor-selective retinoid. LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
14. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Wilson TM, Sporn MB. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
15. Lubet RA, Steele VE, Crowell JA, Yukihiko H, Juliana MM, Eto I, Grubbs CJ. Effects of celecoxib, polyphenon E and rosiglitazone on hydroxybutyl(butyl)- nitrosamine (OH-BBN)-induced urinary bladder cancers in female Fischer-344 rats. Proc Am Assoc Cancer Res 2004;45:725.
16. Wagstaff AJ Goa KL. Spotlight on rosiglitazone in the management of type 2 diabetes mellitus. Treat Endocrinol 2002;1:411-14.
17. Corton JC, Lapinskas PJ, Gonzalex FJ. Central role of PPAR alpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mut Res 2000;448:139-51.
18. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000;40:491-518.
19. Dormandy JA, Eckland D, Erdmann E, Benedetti MM, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macro Vascular Events): a randomized controlled trial. Lancet 2005;366:1279-90.
20. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002;77:23534-43.
21. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 2005;10:295-309.
22. Dominick MA, White MR, Sanderson TP, Van Vleet T, Cohen SM, Arnold LE, Cano M, Tannehill GS, Moehlenkamp JD, Waites CR, Schilling BE. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006;34:903-20.
23. Cohen SM, Murasaki G, Fukushima S, Greenfield RE. Effect of regenerative hyperplasia on the urinary bladder: carcinogenicity of sodium saccharin and N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formaide. Cancer Res 1982;42:65-71.